Interleukin-1 receptor antagonist (IL-1ra) is an important modulator of IL-1 activity in a variety of tissues. IL-1ra is differentially produced by different cell types as a 22-26-kD secreted peptide (sIL-1ra) and/or a smaller 16-or 18-kD intracellular peptide (icIL-1ra). This study was undertaken to evaluate the production of IL-1ra in the human cornea. IL-1ra mRNA can be detected in early passage human corneal epithelial cells and corneal stromal fibroblasts and is significantly enhanced by IL-1. Corneal endothelial cells do not express IL-1ra mRNA. Immunohistochemical studies of cultured corneal cells and whole human cornea demonstrate IL-1ra protein production by both the epithelial and stromal cells but not the endothelial cells. Reverse transcriptase polymerase chain reaction, ELISA, and immunoprecipitation studies indicate that corneal epithelial cells are capable of producing both icIL-1ra and sIL-1ra forms of IL-1ra whereas the corneal stromal cells produce only icIL1ra. In addition to the larger 18-kD icIL-1ra, both corneal epithelial and stromal cells are also capable of producing a smaller recently described 16-kD icIL-1ra. Thus, the differential production of IL-1ra in the human cornea is unique; whereas both epithelial and stromal cells produce icIL-1ra (type 1 and type 2), the epithelial cells appear to also produce sIL-1ra. It is proposed that these IL-1ra proteins may play an important role in regulating IL-1-induced corneal inflammation.
Introduction
Cytokines have been implicated as important mediators of inflammation and tissue damage in the cornea (1) (2) (3) (4) (5) (6) . It has been demonstrated by our group and others that corneal cells are capable of producing a number of inflammatory cytokines including the potent immunomodulating cytokine interleukin 1 (IL-1) (7) (8) (9) (10) (11) (12) (13) (14) . Increased tissue IL-1 production has been detected in many inflammatory disease states ( 15, 16) . In the eye, intravitreal injection of IL-1 produces an acute anterior uveitis in animal models (1) (2) (3) and release of IL-I from implanted intracomeal pellets results in corneal neovascularization (17) . Corneal inflammation and neovascularization have been reported in transgenic mice in which high intraocular constitutive production of IL-If3 was generated by using a crystalline gene promotor construct (18, 19) . Furthermore, the addition of IL-1 to cultured corneal cells augments the production of interleukin 8 (IL-8) and the expression of intracellular adhesion molecule-I (ICAM-1 ) which could initiate the inflammatory cascade in the cornea (20, 21 ) .
Factors which inhibit the effect of IL-I on various target cells may play an important role in modulating corneal inflammation. The IL-I receptor antagonist (IL-Ira)' is a recently characterized molecule that acts as a pure antagonist of biologically active IL-i (22, 23) . IL-ira blocks cellular responses to IL-I by binding almost irreversibly to the IL-I receptor without triggering signal transduction (24, 25) . Alternatively spliced products of the IL-Ira gene result in two forms of IL-Ira designated secreted IL-Ira (sIL-ira) and intracellular IL-Ira (icILIra) which are produced differentially in various cell types and may have distinct biologic roles in modulating IL-i-induced responses (26) . For example monocytes, macrophages, neutrophils, and hepatocytes have been reported to secrete sIL-ira whereas icIL-ira is produced by fibroblasts, macrophages, and epithelial cells (26) . In addition, a second smaller form of icILira ( 16 kD) has been recently described which appears to have a similar function as the larger 18 -kD form of icIL-ira (27, 28) . As an antagonist of IL-1, IL-ira has been demonstrated to inhibit IL-i inducible events both in vitro and in vivo (29) (30) (31) (32) (33) (34) . We have demonstrated that the administration of IL-ira effectively blocks the onset of IL-i -induced uveitis in a rabbit model (35) . However, little is known regarding the production and regulation of IL-Ira in the eye. In this investigation we examine the production of sIL-ira and icIL-Ira in human corneal cells and whole cornea. The production of IL Determination of secreted and cell-associated IL-ira bv ELISA. Cultured human corneal epithelial cells and human corneal stromal fibroblasts were grown to near confluence then either treated with fresh basal media (unstimulated) or media supplemented with recombinant human IL-la (20) U/ml) (Genzyme) for 48 h. Cell supernatants were collected and stored at -20°C. Cell lysates were prepared by collecting cultured cells using 10( mM EDTA in HBSS (Ca-+/Mg-free) at 4°C and centrifugation ( 1,500 g) for 10 min. Cell pellets were lysed in PBS with 1% NP-40, 10 mM EDTA, 2 mM PMSF. and 10 pg/ml each of Leupeptin, Pepstatin A. Antipain, Chymostatin (Sigma Chemical Co., St. Louis, MO) on ice for 20 min. then clarified by centrifugation (10,000 g for 20 min at 4°C). Both cell lysates and tissue culture supernatants were tested for IL-I ra using a commercially available ELISA kit (R&D Systems, Minneapolis, MN).
Northern blot analysis. For Northern blot analysis. corneal epithelial cells and stromal fibroblasts were grown to near confluence then either treated with fresh basal media (unstimulated) or media supplemented with recombinant human IL-la (20 U/ml) (Genzyme) for 6 h prior to cell harvest. Poly(A)+ mRNA was isolated by the oligo(dT)-cellulose affinity chromatography method (36) and mRNA levels were determined by Northern blot analysis as previously described (37 icIL-lra 5'-GAA GTT GAG TTA GAG TCT GAA A. for sIL-lra 5'-GAA TGG AAA TCT GCA GAG GCC TCC GC and 5 '-TGA CAT TTG GTC CTT GCA AGT A, as second primer for both icIL-Ira and sIL-Ira, for common IL-lra sequence 5'-GCA AGA TGC AAG CCT TCA GAA TCT GGG and 5 '-GCT GGT CAG CTT CCA TCG CTG TGC A. Reverse transcriptase products were subjected to 25 We have previously used this antibody in immunoprecipitation/Western blotting assays and have observed that it precipitates a 1 7-kD band from solutions of recombinant human IL-1 ra (data not shown). After binding antibody, protein-A sepharose was recovered by centrifugation ( 1000 g) for 10 min and washed three times in TBS. Samples were then eluted into 25 pl of SDS sample buffer containing 2-Me, heated for 5 min at 950C, microfuged for I min, and subjected to electrophoresis through 15% acrylamide SDS gels and autoradiography at -80'C using Kodak X-OMAT AR film. PMA-differentiated U937 monocytic cells (IL-Ira producer) (39) served as a positive control and the G361 human melanoma cell line (non-IL-lra producer) was used as a negative control for these studies.
Results
Expression of IL-Ira m7RNA in human cornzeal epithelial and stromal cells. IL-Ira mRNA expression was measured in cultured human corneal epithelial cells and corneal stromal fibroblasts by Northern blot analysis (Fig. 1) . As Production of IL-Ira protein by human corneal epithelial and stromal cells. The production of IL-Ira peptide by corneal epithelial cells and stromal fibroblasts was determined by immunohistochemistry (Fig. 2) . In this representative figure, monolayers of both corneal epithelial and stromal cells stain positively for IL-Ira using a primary anti-human IL-Ira antibody (Fig. 2, A and C) . The specificity of this result is confirmed by the absence of staining when pre-immune IgG is used as the primary antibody (Fig. 2, B and D) . These control slides were stained with methylene blue for visualization of cellular morphology. Thus, both human corneal epithelial and stromal cells produce IL-Ira protein in vitro.
Immunolocalization of IL-Ira in whole human cornea. The production of corneal IL-Ira protein was then immunolocalized in freshly isolated whole human cornea (Fig. 3) . Immunohistochemical staining of this tissue demonstrates prominent staining for IL-Ira in the epithelial layers (EP) of the cornea (Fig. 3 A) especially in the more differentiated suprabasal cells. Likewise, there is definite staining of individual stromal cells (S) in the corneal stroma indicating that these cells also produce IL-Ira (Fig. 3 A, arrow) . In contrast, no IL-Ira is detected in the endothelial layer (EN) of the cornea (Fig. 3 B) . Staining specificity is confirmed by the use of preimmune mouse IgG as a control antibody (Fig. 3 C) . These studies thus localize IL-Ira production to both corneal epithelium and stroma but not to the corneal endothelial layer.
Differential production of icIL-ira and sIL-ira mRNA by human corneal epithelial and stromal cells. Two forms of ILIra have been identified: icIL-ira and sIL-Ira. Using specific IL-Ira oligonucleotide primers, the expression of both icIL-Ira and sIL-Ira mRNA was measured in corneal cells. These two forms of IL-Ira are differentially produced by various cell types and may have distinct intracellular and extracellular biologic roles in mediating IL-I inflammatory responses. After RT-PCR amplification, IL-Ira mRNA is detected in both corneal epithelial cells and stromal fibroblasts (Fig. 4) . Both corneal cell types express the 266-bp PCR product for icIL-ira (Fig. 4,  lanes 3-6) . Unexpectedly, corneal epithelial cells also express sIL-Ira mRNA (201 bp product) both constitutively and after the addition of IL-la to the cultured cells (Fig. 4, lanes 3 and  4) . To our knowledge, this is the first example of a true epithelial cell expressing the secreted form of IL-lra. In contrast, the stromal fibroblasts do not express sIL-Ira mRNA (Fig. 4, lanes  5 and 6) . Neither icIL-Ira mRNA nor sIL-Ira mRNA is detected by RT-PCR in the corneal endothelial cells (data not shown). This is in agreement with the immunohistochemistry studies which failed to demonstrate staining of the endothelial layer with an IL-Ira antibody. Synovial fibroblast mRNA derived from a patient with rheumatoid arthritis serves as a positive control for icIL-Ira and sIL-Ira (Fig. 4, lane I ) and human dermal microvascular endothelial cell mRNA serves as a negative control (no IL-Ira expression) for these studies (Fig. 4,  lane 2 ). Since these RT-PCR studies are not quantitative, no conclusion can be drawn regarding the lack of induction of ILIra by IL-I in this figure (Fig. 4, lanes 3 and 5) compared with the Northern blot in Fig. 1 . Thus, these studies demonstrate the differential expression of icIL-Ira and sIL-Ira mRNA in corneal epithelial and stromal cells as well as the unique production of sIL-Ira mRNA by corneal epithelial cells.
Differential production of IL-Ira protein by human corneal epithelial and stromal cells. IL-Ira in corneal cell lysates and supernatants was also examined by ELISA in triplicate using cells from three different corneas. Significant amounts of IL-Ira are detected in supernatants and cell lysates from unstimulated epithelial cells which increased following the addition of ILla (20 U/ml) to the cultured cells (Fig. 5) . Likewise, cell lysates from corneal stromal fibroblasts (unstimulated and stimulated with IL-la) contain quantities of IL-Ira similar to those detected in the epithelial cell lysates (Fig. 5) . In contrast to corneal epithelial cells, no IL-Ira is detected in stromal cell supernatants. Thus these studies are consistent with our previous PCR studies in Fig. 4 which indicate that human corneal epithelial cells are capable of producing both icIL-Ira and sIL-ira whereas stromal cells apparently produce only icIL-ira.
The production of IL-Ira peptides in corneal epithelial and stromal cells was further examined by cellular metabolic labeling studies with 35S followed by immunoprecipitation with an IL-Ira specific antisera. These studies indicate that both corneal epithelial cells and stromal cells produce both a 16-and 18-kD form of IL-ira (Fig. 6 , lanes I and 2) which is consistent with previously reported sizes of icIL-ira(1) and icIL-lra(2) (27, 28) . Additionally, in the epithelial cells, a 22-kD band is detected which is identical to the previously reported (26) glycosylated secreted form of IL-Ira (Fig. 6, lane 1) . As a positive control, immunoprecipitation studies were carried out with the U937 monocytic cell line which has been reported to produce both the intracellular and secreted forms of IL-Ira (39) . As indicated, bands of 16, 18, and 22 kD are clearly produced by this cell line (Fig. 6, lane 3) . As a negative control, the G361 human melanoma cell line which does not produce IL-Ira was utilized (Fig. 6, lane 4) . These studies further support the unique observation that corneal epithelial cells are capable of producing both secreted and intracellular IL-Ira (type 1 and type 2) whereas stromal cells apparently produce only icIL-ira (type 1 and type 2). Discussion IL-I is a potent immunomodulating cytokine with pleiotrophic effects on a variety of tissues (15, 16) were stained with a monoclonal murine anti-L-Ira antibody followed by secondary alkaline phosphatase conjugated goat anti-mouse IgG. Negative controls included human corneal epithelial cells (B) and corneal stromal fibroblasts (D) stained with preimmune mouse IgG as the primary antibody followed by secondary alkaline phosphatase conjugated goat anti-mouse IgG then counterstained with methylene blue to allow the cellular morphology to be visualized.
tions that corneal cells themselves can produce this cytokine in response to various stimuli (7-9, 13, 14, 43, 44) . Ira with increased production after the addition of IL-la whereas IL-Ira mRNA is expressed in corneal stromal fibroblasts at significant levels only after IL-la induction. IL-Ira protein production is likewise demonstrated in both cultured epithelial and stromal cells by immunohistochemistry. Similarly, immunohistochemical analysis of whole human cornea reveals prominent staining for IL-Ira in the epithelial layer and staining of individual stromal cells within the stromal layer of the cornea. The epithelial layer stained more intensely in the more differentiated suprabasal layer which is consistent with previous reports in which increased IL-Ira was detected in more differentiated epidermal cells (27) . The blasts from other tissues (27, (45) (46) (47) (48) . The relatively large amounts of IL-Ira produced by corneal epithelial cells may indicate that this cytokine antagonist plays an important role in IL-I -induced inflammatory responses in the cornea. In contrast, the endothelial layer demonstrates no immunostaining for ILIra or IL-Ira mRNA which is consistent with prior observations that endothelial cells from other tissues produce no IL-Ira (46) .
Corneal epithelial and stromal cells were further evaluated to determine which type of IL-Ira peptide is produced by these cells. The form designated sIL-Ira is a glycosylated 22-26-kD peptide which was first identified as a product of monocytes and later of neutrophils (46, 49, 50) . Low levels of sIL-Ira have also been reported in dermal and synovial fibroblasts by some investigators while other studies demonstrate no sIL-ira production by these cell types (27, (46) (47) (48) . A second form of IL-Ira designated intracellular IL-Ira (icIL-Ira) is a nonglycosylated 18-kD molecule that resides in a cell-associated compartment (46) . More recently, a smaller 16-kD icIL-1ra (2) peptide has also been described (27, 28) . This intracellular peptide appears to function in a similar fashion as the larger 18 kD icIL-Ira( 1) (27, 28) . Dermal and synovial fibroblasts have been reported to produce significantly more icIL-ira than sILira suggesting that icIL-ira is the major form of this protein synthesized by these cells (47, 48) . Other studies were unable to detect icIL-Ira in endometrial or dermal fibroblasts (27, 46) . Epithelial cells such as keratinocytes have also been reported to produce icIL-ira (27, 46) . Additional epithelial cells found to produce icIL-Ira include retinal pigment epithelial cells, nasal epithelium, and bronchial epithelium (46) . In contrast, sIL-ira has not been previously reported to be produced by any epitheHal cell types.
The differential production of sIL-Ira and icIL-ira in corneal epithelial and stromal cells reported in our study suggests that corneal cells exhibit a unique pattern of IL-Ira cell distribution. We found that human corneal epithelial cells produce both icIL-ira and sIL-ira based on ELISA, RT-PCR, and immunoprecipitation. In contrast, human corneal stromal fibroblasts produce only icIL-Ira and no sIL-ira. Additionally, both corneal epithelial and stromal cells produce the recently described 16-kD icIL-Ira(2). The icIL-Ira peptides may act either extracellularly when released from injured cells or may act intracellularly by binding to IL-1 receptors prior to external expression (27) . It was unexpected to find that corneal epithelial cells are capable of producing sIL-ira. The relevance of this novel observation for corneal biology is unclear but the production of the secreted form of this peptide, in contrast to icIL-Ira, has the advantage of allowing this peptide to be available (secreted) and induced without requiring cell damage or death. This could be particularly important for the integrity and function of the cornea where inflammation, tissue damage, and scarring can result in significant loss of visual acuity. This unique situation contrasts with the epidermis in which keratinocytes are capable of producing icIL-ira but not sIL-lra (27 
